Phase 2Recruiting
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers
- Sponsor
- Memorial Sloan Kettering Cancer Center (Academic or other)
- Enrolment
- 60 planned
- Conditions
- Lung Cancer; Lung Cancer Stage II; Lung Cancer Stage III
- Interventions
- Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Certolizumab; Nivolumab; Paclitaxel
- Ages
- adults, older adults
- Registry
- NCT04991025
From the registry
The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.
Primary outcomes
- Participants complete pathologic response (CPR)